MedImmune spins off Viela Bio with focus on autoimmune therapies
AstraZeneca PLC and its MedImmune LLC division have spun off a new company, Viela Bio, which will be tasked with developing six autoimmune and inflammatory disease candidates. Though operating as an independent entity, Viela’s largest minority shareholder will be AZ.
- Large Molecule
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com